Journal of
Medicinal Plants Research

  • Abbreviation: J. Med. Plants Res.
  • Language: English
  • ISSN: 1996-0875
  • DOI: 10.5897/JMPR
  • Start Year: 2007
  • Published Articles: 3834

Full Length Research Paper

A clinical study on the effects and mechanism of Xuebijing injection in the treatment of traumatic intracranial hematoma

Yong Guo1, Kuipo Yan2,3,4, Jiasheng Fang1*, Jinfang Liu1, Mingyu Zhang1 and Jun Wu1
1Department of Neurosurgery, Xiangya Hospital, Central South University, 410008 Changsha, China. 2Institute of Integrated Traditional Medicine and Western Medicine, Xiangya Hospital, Central South University, 410008 Changsha, China. 3Key Unit of Traditional Chinese Medicine Gan of SATCM, Xiangya Hospital, Central South University, 410008 Changsha, China. 4Key Unit of the 11th Five-year Plan of SATCM in Cerebrosis, Xiangya Hospital, Central South University, 410008 Changsha, China.
Email: [email protected]

  •  Accepted: 06 December 2011
  •  Published: 09 February 2012


Xuebijing injection (XBJ) is one of Chinese materia medica standardized products which was extracted from Salvia miltiorrhiza Bge, Carthamus tinctorius L, Paeonia lactiflora Pall,Ligusticum chuanxiong Hort. and Angelica sinensis, has the actions of activating blood circulation and clear the meridians to melt away toxin factor. Our aim was to observe whether or not XBJ have neuroprotective effects on the patients with traumatic intracranial hematoma (TICH). If so, we would explain the mechanism involved. Forty patients with TICH were randomly assigned to trial group and a control group (20 patients per group). Routine medication was given to the patients of the two groups, and XBJ was administered intravenously to patients in the trial group additionally. The scores of GCS was recorded pre and post-treatment of the two groups, along with GOS after therapy. We also measured each patient’ volume of the intracranial hematoma and coagulation indexes pre- and post-treatment. In addition, the activities of antioxidative enzymes were also evaluated in the study. XBJ could promoteglasgow coma scale (GCS) and glasgow outcome scale (GOS) after therapy for the trial group compared with the control group (p<0.01). There was a significant post-treatment difference in the intracranial hematoma absorption between the two groups (p<0.01). The plasma levels of fibrinogen and D-dimer in the trial group were significantly decreased after therapy (p<0.01). XBJ also could decrease the serum level of malondialdehyde (MDA), increased the activities of superoxide dismutase (SOD), catalase (CAT) and the serum level of glutathione (GSH). These results suggest that XBJ exerts significant neuroprotective effects to the recovery of patients with TICH safely, which may be likely through the coagulation improvement and antioxidation and antilipid peroxidative properties of its action.


Key words: Xuebijing injection, traumatic intracranial hematoma, clinical study, coagulation, function, oxidative stress.